💊 Drugs A-Z 🧬 Targets 🛠 Tools 📚 Guides
All Drugs Drug Classes Therapeutic Areas Side Effects
Guides Glossary Timeline
Comparisons Drug Journeys Drug Families
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Dabigatran

Phase 4 Approved Small molecule
Half-Life
12-17 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
471.5 g/mol
LogP
1.7
Phase
4

Dabigatran is an oral anticoagulant that directly inhibits thrombin, the enzyme that converts fibrinogen to fibrin at the final step of the clotting cascade. It prevents strokes in atrial fibrillation and treats and prevents venous blood clots. Marketed as Pradaxa, it has the formula C25H25N7O3 and, unlike warfarin, requires no routine coagulation monitoring.

An anticoagulant that directly inhibits thrombin, a key protein in the blood clotting process. It is used to prevent blood clots and strokes in certain patients.

Molecular Weight

471.5100 g/mol

LogP

1.70

TPSA

150.00 Ų

Lipinski RO5

Pass

Drug Classes

B — B - Blood and Blood Forming Organs

Mechanism of Action

Direct thrombin (Factor IIa) inhibitor.

Pharmacokinetics (PK)

Half-Life 12-17 hours

Pharmacodynamics (PD)

Mechanism

Direct thrombin (Factor IIa) inhibitor.

2D Structure

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CN1C2=C(C=C(C=C2)C(=O)N(CCC(=O)O)C3=CC=CC=N3)N=C1CNC4=CC=C(C=C4)C(=N)N

                

                

                
                

                    
InChI

                    
InChI=1S/C25H25N7O3/c1-31-20-10-7-17(25(35)32(13-11-23(33)34)21-4-2-3-12-28-21)14-19(20)30-22(31)15-29-18-8-5-16(6-9-18)24(26)27/h2-10,12,14,29H,11,13,15H2,1H3,(H3,26,27)(H,33,34)

                

                

                

                    
                    

                        
Molecular Formula

                        
C25H25N7O3

                    

                    
                    

                        
HBD / HBA

                        
4 / 7

                    

                    
                    

                        
Rotatable Bonds

                        
9

                    

                    
                    
                    

                        
Heavy Atoms

                        
35

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            F2 (Thrombin)
                            Inhibitor
                        

                        
                        Primary Target
                        
                    

                    
                    

                        

                            ABCB1 (P-glycoprotein)
                            Substrate
                        

                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Major


                            
                                Dabigatran + Ibuprofen
                            
                        

                        
                        
Ibuprofen with dabigatran increases GI bleeding risk through additive effects; dabigatran itself carries a higher inherent GI bleeding risk than other DOACs.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Dabigatran + Diltiazem
                            
                        

                        
                        
Diltiazem increases dabigatran plasma levels through P-glycoprotein inhibition, potentially raising bleeding risk without a change in INR (dabigatran has no INR to monitor).

                        
                    
                    
                    
                        

                            

  
  Major


                            
                                Dabigatran + Cyclosporine
                            
                        

                        
                        
Cyclosporine dramatically increases dabigatran exposure through P-gp inhibition, raising the risk of serious or life-threatening bleeding.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Dabigatran + Aspirin
                            
                        

                        
                        
Low-dose aspirin combined with dabigatran increases bleeding risk; clinical evidence suggests a 2-fold increase in major bleeding events.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Frequently Asked Questions

                

                    
                    

                        
                        

                            
An anticoagulant that directly inhibits thrombin, a key protein in the blood clotting process. It is used to prevent blood clots and strokes in certain patients.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Direct thrombin (Factor IIa) inhibitor.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Dabigatran: Half-life: 12-17 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Dabigatran is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Apixaban
                            Small molecule
                        
                        
                        
                            Clopidogrel
                            Small molecule
                        
                        
                        
                            Edoxaban
                            Small molecule
                        
                        
                        
                            Rivaroxaban
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 216210.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Medical Disclaimer

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.